MTOR and hepatocellular carcinoma: To further elucidate whether AKT/mTOR plays a specific role in PRMT4-mediated biological processes in HCC cells, rescue experiments were conducted using a specific inhibitor of AKT (1 μM MK2206) or mTOR (100 nM rapamycin).